Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication. 

Higher fasting blood glucose an independent risk factor for developing hypertension

11 Jan 2019
Healthcare providers should provide appropriate advice on the appropriate adjustments for diabetic patients during the fasting month of Ramadan.

Higher fasting blood glucose predicts the development of hypertension, reports a study involving a general Japanese population.

Overall, 10,157 participants (mean age 48.9 percent; 43.4 percent men) without diabetes or hypertension in 2014 were included. After several adjustments, higher baseline blood glucose level was found to be an independent risk factor for hypertension (odds ratio [OR], 1.176; 95 percent CI, 1.086–1.275). Other risk factors included ageing, female sex, higher body mass index (BMI), drinking habits and higher serum uric acid.

Stratification by sex revealed that higher baseline blood glucose level was predictive of hypertension in both women (OR, 1.295; 1.135–1.478) and men (OR, 1.108; 1.001–1.227). When the same analysis was performed using glycated haemoglobin instead of blood glucose, the former did not present to be a risk for hypertension.

“Further studies are needed to determine if treatment for elevated blood glucose can prevent developing hypertension,” the authors said.

A retrospective 5-year cohort study was conducted to identify whether higher fasting blood glucose levels predicted hypertension by a large-scale longitudinal design. Data from 13,201 Japanese individuals who underwent annual medical examinations in 2004 were used and re-evaluated 5 years later. Participants included those without diabetes or hypertension aged 30–85 years in 2004.

The authors calculated the cumulative incidences of hypertension over 5 years in each 10 mg/dl of fasting blood glucose levels. In addition, they examined risk factors and calculated ORs for developing hypertension after adjustments for age, sex, BMI, smoking and drinking habits, dyslipidaemia, chronic kidney disease, serum uric acid, and fasting blood glucose levels by logistic regression analysis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication.